Q-omics provides the consensus-scored RPS6P8 profile across patient tissues and cancer cell-line models. RPS6P8 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS6P8 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPS6P8 RNA expression shows 9,909 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where RPS6P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P8 survival associations across molecular data types. RPS6P8 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P8 RNA expression–survival associations across cancer types. High RPS6P8 expression shows unfavorable associations in ACC, LIHC, UCEC, KIRC and LUAD, but favorable associations in THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS6P8 RNA expression.
This table summarizes RPS6P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P8 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, KIRC, LUSC and PRAD. The COAD box plot shows higher RPS6P8 RNA expression in tumor versus normal tissue (log2 FC = +0.208, t-test p < 0.001).
This table shows molecular features associated with RPS6P8 in patient tissues and cancer cell lines. In patient samples, RPS6P8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
